Pfizer Inc. Files Definitive Proxy Statement for 2024 Annual Meeting

Ticker: PFE · Form: DEF 14A · Filed: Mar 14, 2024 · CIK: 78003

Pfizer Inc DEF 14A Filing Summary
FieldDetail
CompanyPfizer Inc (PFE)
Form TypeDEF 14A
Filed DateMar 14, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$58.5 b, $58.5B, $9.2B
Sentimentneutral

Sentiment: neutral

Topics: Pfizer, Proxy Statement, DEF 14A, Executive Compensation, Annual Meeting

TL;DR

<b>Pfizer Inc. has filed its definitive proxy statement for the 2024 Annual Meeting, detailing executive compensation and corporate governance matters.</b>

AI Summary

PFIZER INC (PFE) filed a Proxy Statement (DEF 14A) with the SEC on March 14, 2024. Pfizer Inc. filed a DEF 14A form on March 14, 2024, for its 2024 Annual Meeting of Stockholders. The filing covers the fiscal year ending December 31, 2023, with comparative data for 2022, 2021, and 2020. Key executive compensation components include stock and option awards, equity awards granted, and changes in pension values. The company's principal executive offices are located at 66 Hudson Boulevard East, New York, NY 10001-2192. Pfizer Inc. is classified under the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking PFIZER INC, this filing contains several important signals. This filing provides crucial information for shareholders to make informed voting decisions on matters presented at the annual meeting, including executive compensation. The detailed breakdown of executive compensation components allows shareholders to assess the alignment between pay and company performance.

Risk Assessment

Risk Level: medium — PFIZER INC shows moderate risk based on this filing. The filing is a routine proxy statement, but the complexity of executive compensation and potential shareholder proposals introduce a medium level of risk regarding investor sentiment and engagement.

Analyst Insight

Shareholders should carefully review the executive compensation details and any proposed resolutions to make informed voting decisions.

Key Numbers

  • 2023-12-31 — Fiscal Year End (FISCAL YEAR END)
  • 2024-03-14 — Filing Date (DATE AS OF CHANGE)
  • 20240425 — Period of Report (CONFORMED PERIOD OF REPORT)

Key Players & Entities

  • PFIZER INC (company) — FILER
  • 2024-03-14 (date) — FILED AS OF DATE
  • 20240425 (date) — CONFORMED PERIOD OF REPORT
  • 66 HUDSON BOULEVARD EAST (address) — BUSINESS ADDRESS STREET 1
  • NEW YORK (location) — BUSINESS ADDRESS CITY
  • 10001-2192 (postal_code) — BUSINESS ADDRESS ZIP
  • 2127332323 (phone_number) — BUSINESS PHONE
  • 2834 (sic_code) — STANDARD INDUSTRIAL CLASSIFICATION

FAQ

When did PFIZER INC file this DEF 14A?

PFIZER INC filed this Proxy Statement (DEF 14A) with the SEC on March 14, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by PFIZER INC (PFE).

Where can I read the original DEF 14A filing from PFIZER INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by PFIZER INC.

What are the key takeaways from PFIZER INC's DEF 14A?

PFIZER INC filed this DEF 14A on March 14, 2024. Key takeaways: Pfizer Inc. filed a DEF 14A form on March 14, 2024, for its 2024 Annual Meeting of Stockholders.. The filing covers the fiscal year ending December 31, 2023, with comparative data for 2022, 2021, and 2020.. Key executive compensation components include stock and option awards, equity awards granted, and changes in pension values..

Is PFIZER INC a risky investment based on this filing?

Based on this DEF 14A, PFIZER INC presents a moderate-risk profile. The filing is a routine proxy statement, but the complexity of executive compensation and potential shareholder proposals introduce a medium level of risk regarding investor sentiment and engagement.

What should investors do after reading PFIZER INC's DEF 14A?

Shareholders should carefully review the executive compensation details and any proposed resolutions to make informed voting decisions. The overall sentiment from this filing is neutral.

How does PFIZER INC compare to its industry peers?

Pfizer Inc. operates within the Pharmaceutical Preparations industry, a sector focused on the research, development, manufacturing, and marketing of drugs and medicines.

Are there regulatory concerns for PFIZER INC?

As a publicly traded company, Pfizer Inc. is subject to the regulations of the Securities and Exchange Commission (SEC), particularly regarding proxy solicitations and corporate disclosures.

Industry Context

Pfizer Inc. operates within the Pharmaceutical Preparations industry, a sector focused on the research, development, manufacturing, and marketing of drugs and medicines.

Regulatory Implications

As a publicly traded company, Pfizer Inc. is subject to the regulations of the Securities and Exchange Commission (SEC), particularly regarding proxy solicitations and corporate disclosures.

What Investors Should Do

  1. Review the detailed executive compensation packages for named executive officers.
  2. Examine any shareholder proposals and the board's recommendations.
  3. Understand the voting procedures and deadlines for the upcoming annual meeting.

Key Dates

  • 2024-03-14: Filing Date — Definitive Proxy Statement filed
  • 2024-04-25: Period of Report — Covers the period leading up to the 2024 Annual Meeting

Year-Over-Year Comparison

This filing is a DEF 14A, a definitive proxy statement, which is a standard annual filing for public companies to solicit proxies from shareholders for their annual meetings.

Filing Stats: 4,436 words · 18 min read · ~15 pages · Grade level 14.1 · Accepted 2024-03-14 09:03:08

Key Financial Figures

  • $58.5 b — full year 2023, we reported revenues of $58.5 billion, reflecting an operational decrea
  • $58.5B — atients Treated Shareholder Returns ~$58.5B ~618M $9.2B in 2023 patients treat
  • $9.2B — Shareholder Returns ~$58.5B ~618M $9.2B in 2023 patients treated globally wi

Filing Documents

— Election of Directors

Item 1 — Election of Directors 5 Criteria for Board Membership 5 Our 202 4 Director Nominees 7 Selection of Candidates 5 Director Nominees 10 Director Independence 6 Governance 16 Overview 16 Governance & Sustainability Committee Report 22 Governance Materials Available on Our Website 16 Regulatory and Compliance Committee Report 23 Board Leadership Structure 16 Shareholder Outreach 24 The Board's Role in Risk Oversight 17 Public Policy Engagement and Political Participation 27 The Board's Role in Succession Planning 18 Pfizer Policies on Business Conduct 29 Evaluation of Board Effectiveness 19 Other Governance Practices and Policies 30 Board and Committee Information 19 Non-Employee Director Compensation 31 202 3 Director Compensation Table 32 Securities Ownership 33 Beneficial Owners 34 Delinquent Section 16(a) Reports 34

— Ratification of Selection of Independent Registered Public Accounting Firm

Item 2 — Ratification of Selection of Independent Registered Public Accounting Firm 35 Audit and Non-Audit Fees 36 Audit Committee Report 37

— Approval of the Amended and Restated Pfizer Inc. 2019 Stock Plan

Item 3 — Approval of the Amended and Restated Pfizer Inc. 2019 Stock Plan 38

— 2024 Advisory Approval of Executive Compensation

Item 4 — 2024 Advisory Approval of Executive Compensation 47 2023 Advisory Vote on Executive Compensation 47 2024 Advisory Vote on Executive Compensation 48 2023 Pay-for-Performance 47 Compensation Committee Report 49

Executive Compensation

Executive Compensation 50 Compensation Discussion and Analysis 50 Compensation Tables 73 Executive Summary 51 Financial Measures 94 Shareholder Proposals 95

— Adopt an Independent Board Chair Policy

Item 5 — Adopt an Independent Board Chair Policy 95

— Amend Director Resignation Processes

Item 7 — Amend Director Resignation Processes 101

— Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures

Item 6 — Publish a Congruency Report on Political, Lobbying, Electioneering Expenditures 98 Ite m 8 — Publish a Report on Corporate Contributions 103 Annual Meeting Information 106 Annual Meeting 106 Other Business 111 Voting 107 Submitting Proxy Proposals and Director Nominations for the 202 5 Annual Meeting 112 Proxy Materials 110 Other Questions 111 Annex 1 — Amended and Restated Pfizer I n c. 2019 Stock Plan I Table of C ontents A Letter from Pfizer's Chairman & Chief Executive Officer Dear Shareholders, While 2023 was a year of several challenges, it was also a year of significant accomplishments. A year that I believe sets up our company for incredible progress in 2024 and beyond, as we celebrate 175 years of breakthrough innovations that serve patients around the world. First, the hard truth. We missed our 2023 initial projections, largely due to the decline in sales of our COVID-19 products. We took corrective steps. We eliminated many uncertainties related to COVID-19 products and reduced COVID-19 product inventory to reflect anticipated future demand; we improved our commercial structure; and we launched a cost-realignment program to right-size our cost base. Difficult, but necessary, decisions were made, enabling us to be more efficient and effective. I am proud that we met our challenges with courage, compassion, and renewed commitment to our purpose. In terms of achievements, there were many in 2023, among them: Approximately 618 million patients around the world were treated with our medicines and vaccines i ; We received a record number of FDA approvals for new molecular entities; We completed our acquisition of Seagen, a critical step in our ambition to end cancer as we know it. These accomplishments, combined with the resilience of our colleagues, are why I am optimistic about the future of Pfizer and what we will deliver to patients. Patient Impact In 2022, we set an ambitious goal of changing one billion l

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.